With the release of various new drugs over the past decade, treatment results for multiple myeloma have been gradually improving. This is because as options vary, opportunities for "customized treatment" to select drugs depending on patients expand.

Medical staff's attention is focused on which patients should be used to maximize the effectiveness. In particular, third-drug therapy centered on second-generation proteasome inhibitors (PI) is a trend in patients with first recurrence.

As KRd therapy (Carfilzomib+ Revlimid +Dexamethasone) centered on Kyprolis and IRd therapy (Ixazomib+Revlimid+Dexamethason) centered on Ninlaro compete, the process of identifying appropriate drug choices cons